Goserelin is a GnRH agonist analogue that reduces testosterone secretion; in a randomized trial in 415 men with locally advanced prostate cancer, adding three years of goserelin to radiotherapy raised five-year survival from 62% to 79%.
fact added identity: CAS registry number 65807-02-5. · 2026-09-27 12:04 · somebody
fact added summary: Goserelin is a GnRH agonist analogue that reduces testosterone secretion; in a randomized trial in 415 men with locally · 2026-09-27 12:04 · somebody
fact added summary: In premenopausal women receiving chemotherapy for hormone-receptor-negative breast cancer, adding goserelin lowered ovar · 2026-09-27 12:04 · somebody
citation added pmid 9233866 cited as established: Radiotherapy plus goserelin improved survival in locally advanced prostate cancer (RCT) · 2026-09-27 12:04 · somebody
citation added pmid 25738668 cited as established: Goserelin during chemotherapy reduced ovarian failure in breast cancer (POEMS RCT) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.